Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in The Lancet The Official Spokesman of Blue Nile State Government said the Council of Ministers also heard updating from Health Minister about chikungunya fever and the preventive efforts made by ...
Chikungunya-like reactions included “fever, joint pain, headache, rash, and can also include cardiac and neurologic conditions which were serious in two cases,” Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, who was not inv...
Risk of yellow fever virus transmission in the Asia-Pacific region Article Open access 16 November 2020 Evaluating vector competence for Yellow fever in the Caribbean Article Open access 09 February 2024 Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and ...
Feb. 18, 2025 – The FDA has approved a new vaccine to protect againstchikungunya. This first-of-its-kind shot is approved to prevent this viral disease in people ages 12 and older. Chikungunya, caused by the chikungunya virus (CHIKV) and spread throughmosquito bites, leads to fever, rash...
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers. On track for commercial launch in the U.S. in the first half of 2025. A Tropical Disease Priority Review V
Saint Herblain (France),February 5, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in theUnited Kingdom(UK) for the world’...
Saint Herblain (France), February 5, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for ...
Saint-Herblain (France), August 29, 2023–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has completed screening validation of the Company’s regulatory application for marketing approval of its single-shot chikungunya vaccin...
Recently, a chikungunya virus-like particle vaccine and a recombinant measles-virus-based chikungunya one have been tried, each one in a short phase I trial (25 and 26 patients, respectively), in which both showed the induction of chikungunya virus neutralizing antibodies in 100% of the ...
Cefixime and Fluoroquinolones like Ofloxacin may be given. A live attenuated vaccine has been developed for prevention. Prevention consists of minimizing mosquito exposure